REFERENCES
- Ling TC, Johnston BT. Esophageal investigations in connective tissue disease which tests are most appropriate? J Clin Gastro-enterol. 2001;32:33–6.
- Patti MG, Gasper WJ, Fisichella PM, Nipomnick I, Palazzo F. Gastroesophageal reflux disease and connective tissue disorders: pathophysiology and implications for treatment. J Gastrointest Surg. 2008;12:1900–6.
- Daruwala C, Mercogliano G, Harder TP. Gastrointestinal mani-festations of systemic lupus erythematosus and scleroderma. Clin Med Insights Gastroenterol. 2009;2:7–12.
- Chong VH, Wang CL. Higher prevalence of gastrointestinal symptoms among patients with rheumatic disorders. Singapore Med J. 2008;48:419–24.
- Ebert EC. The gastrointestinal complications of myositis. Ali-ment Pharmacol Ther. 2010;31:359–65.
- Domsic R, Fasanella K, Bielefeldt K. Gastrointestinal manifes-tations of systemic sclerosis. Dig Dis Sci. 2008;53:1163–74.
- Volter F, Fain 0, Mathieu E, Thomas M. Esophageal function and Sjögren's syndrome. Dig Dis Sci. 2004;49:248–53.
- Marshall JB, Kretschmar JM, Gerhardt DC, Winship DH, Winn D, Treadwell EL, et al. Gastrointestinal manifestations of mixed connective tissue disease. Gastroenterology. 1990;98:1232–8.
- Fujiwara Y, Arakawa T. Epidemiology and clinical characteris-tics of GERD in the Japanese population. J Gastroenterol. 2009;44:518–34.
- Hatlebakk JG, Katz PO, Camacho-Lobato L, Cate11 DO. Proton pump inhibitors: better acid suppression when taken before ameal than without a meal. Aliment Pharmacol Ther. 2000;14: 1267–72.
- Morise K, Iizuka A, Inagaki T, Sugie M, Matsunaga Y, Nakata K, et al. Clinical effect of omeprazole, a gastric proton pump inhibitor-comparative study on morning dose and bed-time dose in the treatment of peptic ulcer. Yakuri to Rinsyo. 1988;16: 593–608.
- Shinomura K, Kaneyama S, Miyazaki Y, Okuda S, Iiishi H, Himeno S, et al. Mod Phys. 1994;14:69-84.
- Tateno M, Nakamura M. Phase I study of lansoprazole (AG-1749) antiulcer agent-capsule form-. Rinsyo Iyaku. 1991;7: 51–62.
- Yasuda S, Ohnishi A, Ogawa T, Tomono Y, Hasegawa J, Nakai H, et al. Pharmacokinetic properties of E3810, a new proton pump inhibitor, in healthy male volunteers. Int J Clin Pharmacol Ther. 1994;32:466–73.
- Kusano M, Shimoyama Y, Sugimoto S, Kawamura 0, Maeda M, Minashi K, et al. Development and evaluation of FSSG: fre-quency scale for the symptoms of GERD. J Gastroenterol. 2004;39: 888–91.
- Dimenas E, Glise H, Hallerback B, Hemqvist H, Svedlund J, Wiklund I. Well-being and gastrointestinal symptoms among patients referred to endoscopy owing to suspected duodenal ulcer. Scand J Gastroenterol. 1995;30:1046–52.
- Kinoshita Y, Ishihara S. Causes of, and therapeutic approaches for, proton pump inhibitor-resistant gastroesophageal reflux dis-ease in Asia. Therap Adv Gastroenterol. 2008;1:191–9.
- Fass R, Sifrim D. Management of heartburn not responding to proton pump inhibitors. Gut. 2009;58:295–309.
- Miki M, Adachi K, Azumi T, Koshino K, Furuta K, Kinoshita Y. A comparative study of intragastric acidity during post-breakfast and pre-dinner administration of low-dose proton pump inhibi-tors: a randomized three-way cross over study. Aliment Phar-macol Ther. 2006;24:1445–51.
- Xie HG, Stein CM, Kim RB, Wilikinson GR, Flockhart DA, Wood AJ. Allelic, genotypic and phenotypic distributions of 5-mephenytoin 4'-hydroxylase (CYP2C19) in healthy Caucasian populations of European descent throughout the world. Pharma-cogenetics. 1999;9:539–49.
- Furuta T, Shirai N, Kodaira M, Sugimoto M, Nogaki A, Kuriy-ama S, et al. Pharmacogenomics-based tailored versus standard therapeutic regimen for eradication of H. pylori. Clin Pharmacol Ther. 2007;81:521–8.